Gilead Sciences Inc.: Access Program
Posted: 3 Apr 2010
Date Written: February 3, 2010
Gilead Sciences, the U.S. leader in HIV/AIDS medicines, with global sales of $5.4 billion in 2009, had undertaken several innovative actions to make its anti-viral products available to over 100 low- and middle-income countries. Having reached nearly 680,000 patients by the middle of 2009, the company's senior managers contemplated how to reach 2 million patients by 2012.
Suggested Citation: Suggested Citation